What Фонтурацетам Treats: Main Uses and Benefits

The primary therapeutic use of Фонтурацетам is generally considered relevant for supportive relief in neurological and neuropsychiatric domains.

This medicine is applied across domains where additional symptomatic support is needed, addressing groups of symptoms that interfere with daily functioning and create noticeable functional strain. The relevant therapeutic domains may assist in addressing cognitive deficits (such as difficulties with concentration, memory, and attention), providing supportive relief for patients with asthenic syndrome and chronic fatigue, and assisting during the recovery phase following neurovascular events like cerebral ischemia or traumatic brain injury.

“This approach may provide support to the patient during difficult episodes, contributing to easing distress and assisting with maintaining a sense of stability when symptoms are more noticeable.”

The medicine is relevant in clinical settings where patients experience conditions characterized by periods of heightened symptoms, and it may provide support for mental effort in demanding periods. Its use, for example, may assist with persistent exhaustion and physical weariness, while its cognitive support may contribute to improved day-to-day comfort during symptomatic periods.

---

Quick Fact: Relief for Asthenic Symptoms

Domain	Symptom Focus	Primary Benefit
Energy	Persistent exhaustion, physical weariness	Contributes to supporting vitality
Cognition	Deficits in concentration and memory	May assist with functional stability in mental performance
Context	Recovery from neurovascular events	Plays a role in managing overall symptom load

Regulatory References

1. National Library of Medicine (NIH) on Phenylpiracetam

Who Can and Cannot Use Фонтурацетам?

Eligibility for Фонтурацетам (Phenylpiracetam) is defined by specific population rules documented in official regulatory labeling, primarily from the Russian Federation.

Contraindicated Populations (Must Not Use)

The medicine is strictly contraindicated in the following groups:

• Children and adolescents under 18 years of age, as safety and efficacy are not established.
• Pregnant women and women who are breastfeeding (lactating).
• Patients with known hypersensitivity or allergy to Фонтурацетам or any of its components.

Condition-Based Restrictions

Use is permitted in other adults aged 18 years and older, but requires caution in specific cases. Conditional use applies to patients with:

• Severe organic lesions of the liver or kidneys.
• Severe arterial hypertension or atherosclerosis.
• A history of panic attacks or acute psychotic states with agitation.

Summary of Eligibility

The profile establishes absolute prohibitions for pediatric and reproductive populations. For eligible adults, the official labeling mandates special consideration for patients with pre-existing severe cardiovascular, renal, hepatic, or specific psychiatric comorbidities.

Interactions with other medicines and products

Fonturacetam (Phenylpiracetam) may interact with certain medicinal products primarily by enhancing their central effects through pharmacodynamic mechanisms. The official regulatory documents and available pharmacological data indicate that caution is necessary when this medication is used concurrently with other agents that affect the central nervous system (CNS).

Significant Pharmacodynamic Interactions

The most notable interactions are classified based on the potential for additive or increased effect when combined with specific drug categories:

• CNS Depressants: Fonturacetam may enhance the action of drugs that depress the central nervous system. This category includes anxiolytics and antipsychotics (neuroleptics). Concurrent use should be approached with caution due to the risk of increased sedation or other CNS-related effects.
• Monoamine Oxidase (MAO) Inhibitors: The combined use of Fonturacetam with MAO inhibitors is noted to increase the effect of the MAO inhibitor.
• Other Nootropics: Potential for enhanced effects when combined with other nootropic substances.

Interaction-Related Restrictions

The use of Fonturacetam simultaneously with alcohol (ethanol) is restricted. Official labeling specifies that the drug may enhance the depressant action of alcohol, leading to an increased risk of adverse effects. Patients should therefore avoid the consumption of alcoholic beverages during treatment.

Pharmacokinetic Context

While this product is metabolized within the body, it is generally not thought to be metabolized by the Cytochrome P450 enzyme system, which is the primary pathway for many drug-drug pharmacokinetic interactions. This may suggest a lower risk for interactions dependent on CYP450 enzyme inhibition or induction, though the noted pharmacodynamic enhancements remain the central consideration for combined use.

Фонтурацетам (Fonturacetam), chemically known as phenylpiracetam, is a racemic compound whose primary pharmacodynamic activity resides in the (R)-enantiomer. This enantiomer, (R)-phenylpiracetam, acts as an atypical inhibitor of the neuronal dopamine transporter (DAT). By binding to and obstructing the DAT, the reuptake of dopamine from the synaptic cleft into the presynaptic terminal is reduced. This interaction results in an increase in extracellular dopamine concentration within specific brain regions, notably those involved in the mesolimbic pathway.

Further molecular targets include interaction with the norepinephrine transporter (NET) and nicotinic acetylcholine receptors (nAChRs), particularly the alpha4beta2 subtype, where it exhibits binding. As a racetam, it is also posited to act as a positive allosteric modulator of AMPA receptors in the central nervous system, enhancing the function of glutamatergic neurotransmission. The overall effect on monoaminergic and cholinergic pathways results in system-level modulation of neurotransmission.

Administration and Dosage Protocol

The usage of Фонтурацетам (Phenylpiracetam) involves specific methods and timing for its administration. The medicine is for oral use, generally supplied as a tablet.

Dosing and Frequency

For adults, the typical daily dose regimen ranges from 100 mg to 200 mg. This total daily amount may be taken as a single administration or be split into two divided doses. The dose generally follows the standard range for specified conditions.

Administration Conditions and Duration

A specific procedural constraint regarding the time of intake is that administration should be avoided after 3:00 PM (15:00). This restriction is intended to manage the medicine's psychostimulant properties and prevent sleep disruption. The product is not intended for continuous, long-term use; rather, it is administered in defined treatment courses, with the average duration of a full course being one month.

Component	Instruction/Pattern
Route of Administration	Oral (Tablet)
Standard Daily Dose	100 mg to 200 mg
Frequency Pattern	Once daily or in divided doses
Time Constraint	Must be avoided after 3:00 PM (15:00)
Course Duration	Typically an average course of 1 month

Research Evidence / Overview of Studies for Фонтурацетам

This overview summarizes the current landscape of clinical research for Фонтурацетам (Phenylpiracetam) based on available scientific literature. The information describes the types of studies that have been conducted and what outcomes they monitored, focusing on the structure of the evidence rather than any specific clinical advice or recommendations. Study results reflect the specific conditions under which they were conducted, and findings describe group patterns, not personal outcomes.

---

Evidence for use in Asthenic Syndrome and Chronic Fatigue

Research was conducted using study designs that included meta-analyses synthesizing regional data, along with observational clinical programs. These study types were applied in research contexts involving fluctuating or unstable symptoms of asthenia and chronic fatigue. Studies monitored adult patients with a diagnosis of asthenia.

Researchers designed studies to evaluate whether specific outcomes related to systemic or functional imbalance could be measured. They monitored changes using standardized asthenia severity scales and recorded patient-reported outcomes describing perceived discomfort. Data reported patterns related to the measurement of these asthenia scores over defined time intervals. Research describes group patterns that were observed during the study periods, and contributes to understanding short-term changes.

Evidence for this indication is currently considered to be of a Moderate level. A key limitation is that the findings are often derived from regional studies and observational designs, which can introduce differences in methodology. There is limited information from large-scale, international Randomized Controlled Trials (RCTs) in this area.

---

Research on Cognitive Deficits

Research was conducted in populations experiencing cognitive deficits, such as difficulties with concentration and memory, often in conditions where symptoms may vary in intensity. The evidence base includes observational clinical programs and clinical trials that evaluated cognitive function alongside other measured outcomes. Studies monitored adult patients, typically those with cognitive impairment associated with underlying conditions.

Research explored functional measures, utilizing standardized cognitive function assessment scales to monitor changes in performance related to concentration and memory. The studies report how symptoms evolved in the observed populations, and this research contributes to understanding short-term changes.

However, the evidence is limited because the evaluation of cognitive function is frequently reported as a secondary measurement. Evidence exploring cognitive outcomes separate from anti-asthenic properties is not well-established.

---

Understanding Research Gaps and Uncertainty

Research highlights several key limitations, including areas where certainty remains low. A core limitation is that it is observed evidence quality varies across studies; many findings are derived from regional clinical studies and observational designs, rather than being based on an abundance of large-scale, international Randomized Controlled Trials (RCTs). Additionally, in many studies, the sample sizes were modest, which restricts the certainty and generalizability of the findings.

Furthermore, there is limited information for long-term outcomes because follow-up durations were limited across the research landscape. Comparative evidence against other active treatments is lacking, and this research provides context but not individual predictions about personal outcomes.

Key Studies & References

1. Observational Study Investigating Phenylpiracetam Outcomes in Chronic Cerebrovascular Conditions
2. National Library of Medicine (NIH) - Phenylpiracetam clinical literature index

Common questions about Фонтурацетам (FAQ)

Q: Can I take this medication with alcohol?

A: Official drug safety information addresses the use of this medication with alcohol. Regulatory documents either contain an explicit warning against combining the drug with alcohol, or they state that specific interaction studies found no notable issues. The patient information leaflet or product monograph should be consulted for the precise guidance relevant to this drug.

Q: Does it make you sleepy or drowsy?

A: Official drug labeling often lists somnolence (drowsiness) or dizziness as a possible side effect, though these are not experienced by everyone. Due to the potential for these central nervous system effects, regulatory guidance may include a caution regarding driving or operating heavy machinery, as individuals react differently to medication.

Q: Is this medication safe to take during pregnancy or while breastfeeding?

A: The official product information contains specific sections detailing the use of the drug during pregnancy and lactation (breastfeeding). This information includes risk summaries, whether the drug passes into human milk, and clinical data. The most current official labeling should be consulted for definitive guidance regarding use during these periods.

Q: Can I crush or cut the tablets?

A: The method of administration is explicitly described in the regulatory documents. Most drug formulations are designed to be swallowed whole, and instructions will state if the tablet should not be crushed or chewed. If the label does not provide specific instructions allowing modification, the tablet is generally expected to be taken as formulated to ensure the correct release of the medication.

Q: Are there any foods or juices I should avoid when taking this?

A: Official labeling, usually found in the interactions section, lists any known interactions with foods or beverages that could affect how the medication works. For example, some labels caution against combining the medication with certain fruit juices or dairy products. These documents also specify whether the medicine should be taken with or without food.

Q: Can children 2 years old use this?

A: Official drug labeling specifies the approved age range for the medication's use under the 'Pediatric Use' section. If the official indication and dosing instructions do not include children, or specifically a 2-year-old population, the drug is not approved for use in that age group. The official labeling provides confirmation of the approved population.

How to Store and Dispose of Фонтурацетам

The storage and disposal requirements for Фонтурацетам (Phenylpiracetam) are based on the official regulatory labeling from the national health authority where the medicine is approved.

---

Official Storage Conditions

Requirement	Specific Condition
Temperature	Store at a temperature not exceeding 25 C (77 F).
Protection	Store in a dry place and protect from light.
Container	Keep in the original container/packaging.
Child Safety	Must be kept out of the sight and reach of children.

---

These conditions are mandatory to ensure the product maintains its labeled shelf-life of 5 years. When the product is unused, expired, or damaged, it must be disposed of in accordance with local regulatory requirements for pharmaceutical waste.